Mizuho analyst Graig Suvannavejh raised the firm’s price target on Intra-Cellular to $82 from $76 and keeps a Buy rating on the shares. Ahead of Q4 earnings, the firm updated models and revised 12-month price targets in the biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ITCI:
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
- JPMorgan ups Intra-Cellular target, places on ‘Positive Catalyst Watch’
- Intra-Cellular CEO sells $2.27M in common stock
- Intra-Cellular initiated with Outperform on Caplyta growth at Baird
- Intra-Cellular initiated with an Outperform at Baird
